What is the appropriate evaluation and management of chest pain in a patient with recent cannabis use?

Evaluation of Chest Pain in Cannabis Users

Evaluate chest pain in cannabis users using the same systematic approach as any acute chest pain presentation, with heightened awareness for life-threatening cardiovascular complications including acute coronary syndrome, myocarditis, aortic dissection, and spontaneous pneumomediastinum—all of which have documented associations with cannabis use.

Initial Assessment Framework

The 2021 AHA/ACC chest pain guidelines mandate a focused history capturing: symptom characteristics, duration, location/radiation, precipitating factors, relieving factors, and associated symptoms 1. For cannabis users specifically, obtain:

• Timing and pattern of cannabis use: Recent use (within hours), chronic daily use, method of consumption (smoking, vaping), and duration of use history
• Cardiovascular symptoms: Palpitations (present in 45.5% of drug-related chest pain), anxiety (42.5%), dyspnea, diaphoresis, radiation to left arm/jaw/neck 2
• Risk stratification factors: Age, traditional cardiovascular risk factors, family history of aortic disease or early CAD

Immediate Diagnostic Workup

Essential Testing (All Patients)

1. 12-lead ECG immediately 1

   • Look for ST-elevation (myocardial infarction, myopericarditis) 3, 4, 5
   • Diffuse ST-elevation pattern suggests myopericarditis 3
   • Advanced heart block has been reported with cannabis-induced ACS 5

2. High-sensitivity cardiac troponin 1

   • Elevated in myocarditis, ACS, and even some cases of pneumomediastinum 6
   • Serial measurements if initial negative but suspicion remains

3. Chest X-ray

   • Rule out pneumomediastinum (air along mediastinal structures, subcutaneous emphysema) 7, 6
   • Pneumothorax evaluation

Risk-Stratified Advanced Imaging

High-risk features requiring urgent CT angiography:

• Tearing/ripping chest pain radiating to back (aortic dissection documented with cannabis use) 8
• Hemodynamic instability
• Pulse deficits or blood pressure discrepancies

Moderate-risk features requiring cardiac evaluation:

• Positive troponin with ECG changes → Cardiac catheterization for suspected ACS

  • Cannabis users can present with extensive coronary thrombosis even without significant atherosclerosis 9
  • Young patients (20s-30s) with minimal traditional risk factors have presented with significant CAD requiring PCI 10, 5

• Troponin elevation with diffuse ST changes → Cardiac MRI to diagnose myocarditis 3, 4

Atypical chest pain with subcutaneous emphysema or Hamman's sign:

• CT chest with contrast to confirm pneumomediastinum and exclude esophageal rupture (Boerhaave syndrome) 7, 6

Critical Pathophysiologic Considerations

Cannabis causes multiple cardiovascular effects that inform your evaluation 11:

• Acute sympathomimetic surge: Beta-adrenergic tachycardia, hypertension (13.6% of cases), increased myocardial oxygen demand 11, 2
• Prothrombotic state: Direct platelet activation via CB₁/CB₂ receptors, increased thromboxane A₂ production 9
• Vasospasm: Coronary vasoconstriction contributing to ACS 5
• Endothelial dysfunction: Accelerated atherosclerosis in chronic users 10
• Barotrauma: Prolonged breath-holding during inhalation causes alveolar rupture (Macklin effect) leading to pneumomediastinum 7, 6

Age-Specific Risk Assessment

Young adults (<35 years) with cannabis use:

• Lower threshold for cardiac workup despite age—documented cases of severe CAD requiring CABG in chronic users 10
• Consider myocarditis if troponin elevated with diffuse ECG changes 3, 4
• High index of suspicion for pneumomediastinum if recent smoking with pleuritic pain 7, 6

Middle-aged patients (35-55 years):

• Cannabis may accelerate existing atherosclerotic disease 10
• Evaluate as high-risk ACS until proven otherwise
• Document cannabis as modifiable risk factor

Management Pitfalls to Avoid

1. Do not dismiss chest pain in young cannabis users as anxiety: Multiple case reports document MI, myocarditis, and aortic dissection in patients in their 20s-30s 3, 4, 8, 10, 5

2. Do not assume negative initial troponin excludes cardiac pathology: Serial troponins required; some cannabis-induced cardiac events evolve over hours

3. Elevated troponin with pneumomediastinum can occur: Do not reflexively assume ACS without correlating ECG and imaging 6

4. Cannabis co-use with cocaine is common (70% cocaine, 35.7% cannabis in one series): Ask about polysubstance use as this increases cardiovascular risk 2

5. Family history matters: The documented aortic dissection case had family history of aortic disease—cannabis may be a trigger in predisposed individuals 8

Disposition Algorithm

Admit for:

• Any troponin elevation with ECG changes
• Confirmed ACS, myocarditis, or aortic dissection
• Extensive pneumomediastinum requiring observation
• Arrhythmias or heart block 5

Discharge considerations (only after complete workup):

• Negative serial troponins, normal ECG, negative imaging
• Benign pneumomediastinum (small, stable, no secondary causes excluded)
• Clear counseling on cannabis cessation as cardiovascular risk factor
• Cardiology follow-up for risk stratification in chronic users

The evidence demonstrates cannabis is not a benign substance cardiovascularly—treat these patients with the same urgency as other drug-induced chest pain presentations, recognizing the spectrum from benign pneumomediastinum to life-threatening coronary thrombosis.